Company Overview and News

 
CCS to invest Rs6.3bn in new ice cream factory, bottling facility

2017-05-19 lankabusinessonline
May 19, 2017 (LBO) – Ceylon Cold Stores said it is enhancing capacity with investments of 3.8 billion rupees in a new ice cream factory and 2.5 billion rupees in a new bottling facility for beverages.

 
Ceylon Cold Stores March quarter net down 15-pct

2017-05-17 lankabusinessonline
May 17, 2017 (LBO) – Profits at Sri Lanka’s Ceylon Cold Stores group, which has interests in consumer goods and retailing, fell 15 percent to 824 million rupees in the March 2017 quarter from a year earlier, interim accounts showed.

 
Ceylon Chamber forms ‘Dairy Association for Sri Lanka’

2017-03-01 lankabusinessonline
Dairy sector is one of the important sectors of the national economy that has high potential for improving the livelihood and income levels of poorer segments in the society whilst fulfilling the nutritional requirements of the population. Currently, Sri Lanka imports approximately 70 percent of its dairy products requirements spending considerable foreign exchange. Successive Governments have embarked on various initiatives to increase local production with the objective of reaching self-sufficiency in milk production.

 
Ceylon Cold Stores net up 26-pct in December quarter

2017-01-30 lankabusinessonline
Jan 30, 2017 (LBO) – Profits at Sri Lanka’s Ceylon Cold Stores rose 26 percent to 823 million rupees in the December 2016 quarter from a year earlier.

 
MullenLowe moves Sri Lanka operations to ultramodern office

2017-01-10 lankabusinessonline
MullenLowe Sri Lanka, the local office of the MullenLowe network – a member of the Interpublic Group (IPG), will formally unveil its ultra-modern office at 125, Kynsey Road, Colombo – 7, on the 19th of January under the patronage of Hon. Eran Wickramaratne – Deputy Minister of Public Enterprise Development and Member of Parliament (MP) – Chief Guest, Mr. Joseph George – Regional President, South & South East Asia and Group Chairman and CEO, MullenLowe Lintas Group and the regional team.

 
Sri Lanka’s Elephant House pours soft drinks into Europe

2016-10-07 lankabusinessonline
Oct 07, 2016 (LBO) – Sri Lanka’s iconic Elephant House has signed up with a UK-based bottling facility for the production of 1.5 litre PET plastic variants of its much-loved Necto, Cream Soda and Orange Barley beverages.

 
Sri Lankan shares end flat amid foreign outflows

2016-09-27 bizenglish.adaderana.lk
Reuters – Sri Lankan stocks ended steady on Monday, as gains in financial shares were offset by losses in consumer staples, amid foreign outflows and tax hike concerns.

 
MullenLowe duo win Sri Lankan leg of Young Spikes Digital Competition

2016-09-20 bizenglish.adaderana.lk
Chevin Mandawala and Sagar Hiranand of MullenLowe Sri Lanka outshone their peers in the digital category at the Sri Lankan leg of Young Spikes 2016, recently. Their winning idea – Marco Knorrs it – highlighted their intimate understanding and use of digital platforms to increase the strength of Knorr and increase its usage. With this victory, the duo have won the honour of representing Sri Lanka at the Young Spikes Digital Competition to be held during the Spikes Asia Festival of Creativity in Singapore.

 
Sri Lankan shares hit more than 1-mth closing low; large caps down

2016-09-09 bizenglish.adaderana.lk
Reuters – Sri Lanka’s benchmark index hit a more than one-month closing low on Thursday, dragged down by large cap shares, as investors largely stayed on the sidelines amid confusion over falling bond yields, stockbrokers said.

 
Sri Lankan shares slip from 3-month closing high

2016-08-23 bizenglish.adaderana.lk
Reuters – Aug 22 Sri Lankan shares closed slightly weaker on Monday after posting a three-month closing high in the previous session as investors booked profit in beverage and telecom stocks.

 
Sri Lankan shares slip from 10-week high on profit-taking

2016-08-12 bizenglish.adaderana.lk
Reuters – Aug 11 Sri Lankan shares on Thursday slipped from its more-than-10-week high, hit in the previous session, as foreign outflow dented investor sentiment while some investors booked profits in thin trade.

 
Sri Lanka’s Ceylon Cold Stores net up 56-pct in June quarter

2016-07-22 lankabusinessonline
July 22, 2016 (LBO) – Profits at Sri Lanka’s Ceylon Cold Stores, which has interests in consumer goods and retailing, surged 56 percent to 855 million rupees in the June 2016 quarter from a year earlier as revenues rose 30 percent.

 
Sri Lankan shares post 2-wk closing high on foreign buying

2016-07-10 bizenglish.adaderana.lk
Reuters – Sri Lankan shares rose for a third straight session on Friday and posted their highest close in two weeks, as foreign investors continued to buy into banking and diversified stocks after recent losses.

 
Ceylon Cold Stores PLC Joins CSE to Open Trading for July

2016-07-01 lankabusinessonline
Ceylon Cold Stores (CCS) rang the opening bell to commence trading at the Colombo Stock Exchange (CSE) today. The market opening ceremony was organized to mark the first trading day for the month of July.

 
Ceylon Cold Stores PLC Joins CSE to Open Trading for July

2016-07-01 bizenglish.adaderana.lk
Ceylon Cold Stores (CCS) rang the opening bell to commence trading at the Colombo Stock Exchange (CSE) today. The market opening ceremony was organized to mark the first trading day for the month of July.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...